MARKET

RETA

RETA

Reata Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

109.94
+2.37
+2.20%
After Hours: 109.94 0 0.00% 16:31 09/17 EDT
OPEN
107.67
PREV CLOSE
107.57
HIGH
109.98
LOW
106.44
VOLUME
286.03K
TURNOVER
--
52 WEEK HIGH
186.82
52 WEEK LOW
76.34
MARKET CAP
4.00B
P/E (TTM)
-14.2601
1D
5D
1M
3M
1Y
5Y
Reata Pharmaceuticals's Return on Invested Capital Overview
Benzinga Pro data, Reata Pharmaceuticals (NASDAQ:RETA) reported Q2 sales of $2.22 million. Earnings fell to a loss of $60.13 million, resulting in a 9.5% decrease from last quarter.
Benzinga · 16h ago
Why Is Reata Pharmaceuticals, Inc. (RETA) Up 12.2% Since Last Earnings Report?
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/08 15:30
Stanley Druckenmiller is Selling These 12 Stocks
In this article, we discuss the 12 stocks Stanley Druckenmiller is selling. If you want to skip our detailed analysis of these stocks, go directly to the Stanley Druckenmiller is Selling These 5 Stocks. Stanley Druckenmiller, the chief of New York-based Du...
Insider Monkey · 08/24 20:32
Corriente Advisors, LLC Buys Coinbase Global Inc, Reata Pharmaceuticals Inc, QuantumScape Corp, ...
GuruFocus News · 08/18 14:38
Stanley Druckenmiller bet on a vaccine stock and jumped back into streaming giant Netflix
Druckenmiller added new positions in Moderna, General Motors, Airbnb, Netflix and Smartsheet.com in the second quarter.
CNBC.com · 08/16 20:46
AHPI, MDIA, SCPE among mid-day movers
Gainers: Fulcrum Therapeutics (NASDAQ:FULC) +123%. Lightning eMotors (NYSE:ZEV) +52%. 3D Systems (NYSE:DDD) +41%. MediaCo (NASDAQ:MDIA) +40%. Allied Healthcare Products (NASDAQ:AHPI) +27%. Exagen (NASDAQ:XGN) +26%. IMV (NASDAQ:IMV) +23%. Arcturus Therapeut...
Seekingalpha · 08/10 16:44
54 Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.
Benzinga · 08/10 16:02
Fulcrum Therapeutics, Allied Healthcare Products leads healthcare gainers; SmileDirectClub, EyeGate Pharmaceuticals among major losers
Gainers: Fulcrum Therapeutics (NASDAQ:FULC) +84%, Allied Healthcare Products (NASDAQ:AHPI) +39%, IMV (NASDAQ:IMV) +29%, Exagen (NASDAQ:XGN) +26%, Myomo (NYSE:MYO) +22%. Losers: SmileDirectClub (NASDAQ:SDC) -23%, EyeGate Pharmaceuticals (NASDAQ:EYEG) -23%, ...
Seekingalpha · 08/10 15:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RETA. Analyze the recent business situations of Reata Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RETA stock price target is 226.44 with a high estimate of 282.00 and a low estimate of 175.00.
EPS
Institutional Holdings
Institutions: 295
Institutional Holdings: 29.25M
% Owned: 80.39%
Shares Outstanding: 36.39M
TypeInstitutionsShares
Increased
68
3.28M
New
32
338.44K
Decreased
66
1.58M
Sold Out
39
756.50K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/President/Chief Executive Officer/Director
J. Warren Huff
Chief Financial Officer/Chief Operating Officer/Executive Vice President
Manmeet Soni
Executive Vice President
Dawn Bir
Executive Vice President
Colin Meyer
Executive Vice President
Michael Wortley
Independent Director
Martin Edwards
Independent Director
William McClellan
Independent Director
R. Kent McGaughy
Independent Director
Jack Nielsen
Independent Director
Christy Oliger
Independent Director
William Rose
Independent Director
Shamim Ruff
No Data
About RETA
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.

Webull offers kinds of Reata Pharmaceuticals Inc stock information, including NASDAQ:RETA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RETA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RETA stock methods without spending real money on the virtual paper trading platform.